PSYCHOACTIVE DRUG SCREENING

精神活性药物筛查

• 批准号: 2320817
• 负责人: JOHN W FERKANY
• 金额: $ 55万
• 依托单位: NOVA PHARMACEUTICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-07-01 至 1995-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2320817
• 关键词: PSYCHOACTIVE; DRUG; SCREENING

The NIMH Screening Program was established in order to evaluate natural or synthetic compounds with potential central nervous system (CNS) activity from individual scientists engaged in basic or preclinical research. Centrally active natural product extracts are especially of interest in order to search for novel pharmacologic mechanisms. Screening costs are paid for by the NIMH; there are no charges to investigators. Under this contract, investigators may submit compounds for evaluation in receptor- based assays which may be predictive of psychotherapeutic activity. The main purpose of this contract is to aid in the design of new therapeutic agents, to better predict and understand mechanisms of potential side-effects, and to better understand the mechanisms of therapeutic action of new agents. In order to accomplish these broad aims, the NIMH strongly encourages investigators to follow up compounds which display activity (i.e., inhibition of ligand binding or enzyme activity) with additional testing. Additional tests may include, for example, receptor subtypes, preliminary IC50, functional assays, or in vivo activity and will be determined on a case-by-case basis. The NIMH expects that investigators submitting compounds will: 1) publish results obtained from the screening analyses (publications should acknowledge the service provided by the NIMH program); and, 2) provide the NIMH with a copy of the published manuscript. It is planned that the data generated from this program will be entered into an NIMH structure-activity database. This information will serve as a resource to assist in the design and discovery of novel compounds with potential use in the treatment of mental health disorders.

NIMH筛查计划的建立是为了评估自然或 具有潜在中枢神经系统（CNS）活性的合成化合物 来自从事基础或临床前研究的科学家个人。 具有中枢活性的天然产物提取物尤其令人感兴趣， 以寻找新的药理学机制。筛查费用为 由NIMH支付;不向调查人员收费。根据本 合同，研究者可以提交化合物用于受体评估- 基于可以预测心理治疗活性的测定。 该合同的主要目的是帮助设计新的 治疗药物，以更好地预测和理解的机制， 潜在的副作用，并更好地了解机制， 新药剂的治疗作用。为了实现这些广泛的目标， NIMH强烈鼓励研究人员跟踪化合物， 显示活动（即，抑制配体结合或酶活性） 进行额外的测试。其他测试可能包括，例如， 受体亚型、初步IC 50、功能测定或体内 活动，并将在个案基础上确定。 NIMH预计 提交化合物的研究者将：1）公布获得的结果 从筛选分析（出版物应承认服务 （2）向NIMH提供一份 出版的手稿。 计划将输入从该程序生成的数据 NIMH构效数据库中这些信息将作为 一个资源，以协助设计和发现新的化合物， 治疗精神疾病的潜在用途。